Clinical trial
Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or…
NCT00005849 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00005849 |
|---|---|
| Title | Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer |
| Official title | Phase II Study of Bryostatin-1 in Combination With Paclitaxel for Non-Small Cell Lung Cancer |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | bryostatin 1, paclitaxel |
| Enrollment | 15 |
| Start date | Apr 1, 2000 |
| Primary completion | Sep 1, 2002 |
| Completion | Nov 1, 2003 |
| First posted | Apr 26, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: